BackGreat Novel Therapeutics Biotech & Medicals Overview
Great Novel Therapeutics Biotech & Medicals

Great Novel Therapeutics Biotech & Medicals Return on Equity

Latest ROE for Great Novel Therapeutics Biotech & Medicals: -26.46% — see history and peer comparisons.

Get informed when a big investor buys or sells

+ Follow

ROE

-26.46%

Return on Equity

-26.46%

Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.

ROE (Comparison Companies)

Loading

ROE History

Loading

ROE Comparison

Loading

Great Novel Therapeutics Biotech & Medicals (7427.TWO) FAQ

The latest ROE for 7427.TWO is -26.46%. That is below the Healthcare sector average of 13.1%. Investors often review this figure alongside Great Novel Therapeutics Biotech & Medicals's historical trend and sector peers before judging valuation or financial health.

Against Healthcare companies, 7427.TWO currently prints -26.46% for ROE, while the sector average sits near 13.1%. That is roughly 301.9% below the sector mean. Large gaps often invite a closer look at Great Novel Therapeutics Biotech & Medicals's growth, margins, and balance sheet.

Return on Equity shows how effectively Great Novel Therapeutics Biotech & Medicals converts resources into returns. At -26.46%, 7427.TWO may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting 7427.TWO's ROE (-26.46%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Great Novel Therapeutics Biotech & Medicals's ROE against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.